O'Shaughnessy Asset Management’s Harvard Bioscience HBIO Stock Holding History

O'Shaughnessy Asset Management’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,550	Closed	-$65.7K	–	1994
2024 Q1	$65.7K	Sell	1,550 -200	-11%	-$8.99K	﹤0.01%	1640
2023 Q4	$93.6K	Sell	1,750 -313	-15%	-$14.1K	﹤0.01%	1503
2023 Q3	$88.7K	Buy	2,063 +152	+8%	+$7.01K	﹤0.01%	1400
2023 Q2	$105K	Buy	+1,911	New	+$105K	﹤0.01%	1287
2021 Q4	–	Sell	-35	Closed	-$2K	–	1758
2021 Q3	$2K	Buy	35 +14	+67%	+$1.11K	﹤0.01%	2478
2021 Q2	$2K	Buy	+21	New	+$1.49K	﹤0.01%	2303
2019 Q1	–	Sell	-499	Closed	-$16K	–	945
2018 Q4	$16K	Sell	499 -460	-48%	-$18.1K	﹤0.01%	777
2018 Q3	$50K	Hold	959	–	–	﹤0.01%	714
2018 Q2	$51K	Sell	959 -54	-5%	-$2.77K	﹤0.01%	711
2018 Q1	$51K	Buy	+1,013	New	+$45.4K	﹤0.01%	711

Other funds holding HBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAIM

Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return

Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

O'Shaughnessy Asset Management's HBIO Position: Q2 2024 in Review

O'Shaughnessy Asset Management sold out of Harvard Bioscience (HBIO) in Q2 2024, closing a stake of 1,550 shares — an estimated $65.7K sold.

O'Shaughnessy Asset Management first reported a position in HBIO in Q1 2018 and held it in 10 quarters. The position peaked at $105K in Q2 2023. 100 funds tracked by Wall St. Rank hold HBIO as of Q2 2024.

O'Shaughnessy Asset Management reported no remaining Harvard Bioscience position as of Q2 2024 after selling out during the quarter.
O'Shaughnessy Asset Management sold 1,550 Harvard Bioscience shares in Q2 2024, an estimated $65.7K.
O'Shaughnessy Asset Management first reported a position in Harvard Bioscience in Q1 2018 and held it in 10 quarters.
O'Shaughnessy Asset Management's Harvard Bioscience position peaked at $105K in Q2 2023.
100 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2024.

Based on O'Shaughnessy Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.